Evaluating ginkgetin from as a novel agent for sleep promotion through molecular docking and studies.

OBJECTIVES

Sleep impacts the well-being and quality of life of millions. Given conventional pharmacotherapy's limitations and side effects, the quest for adequate and proper sleep promotion is imperative. This study aims to identify a suitable and effective compound for sleep by examining qualified herbal compounds in the PubChem database using methods. Ultimately, the extracted compound (ginkgetin, a bioactive flavonoid from ) through molecular docking by considering the GABAA receptors will be evaluated through the method in an animal model to serve as proof for the findings from the molecular docking process.

MATERIALS AND METHODS

Utilizing a comprehensive approach, this research employed molecular docking to screen 2299 phytochemicals for their affinity towards the GABAA receptor, focusing on the GABA, benzodiazepine, and steroid-binding sites. Ginkgetin emerged as a top candidate due to its high binding affinity. Subsequent electrophysiological assessments in rats treated with extract containing ginkgetin evaluated alterations in sleep architecture, REM, and NREM sleep phases.

RESULTS

Molecular docking identified ginkgetin as possessing the highest binding affinity among the screened phytochemicals. studies corroborated these findings, demonstrating that rats treated with extract significantly enhanced REM and NREM sleep compared to controls.

CONCLUSION

Ginkgetin, derived from , shows promising potential as a novel therapeutic agent for sleep disorders, supported by its strong affinity to key receptor sites and its efficacy in modulating sleep architecture . These findings contribute to the expanding evidence base for the therapeutic use of in sleep promotion and underscore the need for further research to elucidate the mechanisms and clinical applicability of ginkgetin in sleep disorder treatment.